P & L Development
United States Updated 9 July 2026
P & L Development is a finished-dose manufacturer based in United States. It appears in 4 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA and EEC_EAEU. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 21 May 2025 as NAI.
4
registered plants
4 with an FDA FEI number
4
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 21 May 2025 NAI US FDA
- 15 May 2025 NAI US FDA
- 23 April 2025 NAI US FDA
- 31 December 2024 NAI US FDA
- 15 September 2022 NAI US FDA
- 13 November 2018 VAI US FDA
- 26 September 2018 VAI US FDA
- 24 June 2016 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| westbury, United States | 1000306997 |
| Copiague, United States | 2410283 |
| Lynwood, United States | 1000160562 |
| Piedmont, United States | 3013977187 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 3 | 3 |
| EEC_EAEU | 1 | None |
Comparing suppliers?
Choose your molecules and target markets. P & L Development comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 21 May 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates